 | • レポートコード：MRC2301D043 • 出版社/出版日：Transparency Market Research / 2022年11月21日 • レポート形態：英文、PDF、243 ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査書では、世界の持続的腎機能代替療法（CRRT）市場について調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場展望、モード別（緩徐持続的限外濾過（SCUF）、持続的静静脈血液濾過（CVVHF）、持続的静静脈血液透析（CVVHD）、持続的静静脈血液濾過透析（CVVHDF））分析、製品別（透析液・交換液、消耗品、システム）分析、治療法別（腎性、非腎性、複合性）分析、エンドユーザー別（病院、診療所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの内容を整理しました。並びに、当書に掲載されている企業情報には、Baxter International, Inc.、Nipro Corporation、Asahi Kasei Corporation、B. Braun Melsungen AG、Medica SPA、INFOMED SA、Medtronic、Toray Medical Company Limited (Toray Industries, Inc.)などが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・市場展望 ・世界の持続的腎機能代替療法（CRRT）市場規模：モード別 - 緩徐持続的限外濾過（SCUF）の市場規模 - 持続的静静脈血液濾過（CVVHF）の市場規模 - 持続的静静脈血液透析（CVVHD）の市場規模 - 持続的静静脈血液濾過透析（CVVHDF）の市場規模 ・世界の持続的腎機能代替療法（CRRT）市場規模：製品別 - 持続的腎機能代替療法（CRRT）透析液・交換液の市場規模 - 持続的腎機能代替療法（CRRT）消耗品の市場規模 - 持続的腎機能代替療法（CRRT）システムの市場規模 ・世界の持続的腎機能代替療法（CRRT）市場規模：治療法別 - 腎性持続的腎機能代替療法（CRRT）の市場規模 - 非腎性持続的腎機能代替療法（CRRT）の市場規模 - 複合性持続的腎機能代替療法（CRRT）の市場規模 ・世界の持続的腎機能代替療法（CRRT）市場規模：エンドユーザー別 - 病院における市場規模 - 診療所における市場規模 - その他エンドユーザーにおける市場規模 ・世界の持続的腎機能代替療法（CRRT）市場規模：地域別 - 北米の持続的腎機能代替療法（CRRT）市場規模 - ヨーロッパの持続的腎機能代替療法（CRRT）市場規模 - アジア太平洋の持続的腎機能代替療法（CRRT）市場規模 - 中南米の持続的腎機能代替療法（CRRT）市場規模 - 中東・アフリカの持続的腎機能代替療法（CRRT）市場規模 ・競争状況 |
Continuous Renal Replacement Therapy Market – Scope of Report
TMR’s report on the global continuous renal replacement therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global continuous renal replacement therapy market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global continuous renal replacement therapy market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the continuous renal replacement therapy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global continuous renal replacement therapy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global continuous renal replacement therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global continuous renal replacement therapy market.
The report delves into the competitive landscape of the global continuous renal replacement therapy market. Key players operating in the global continuous renal replacement therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global continuous renal replacement therapy market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market continuous renal replacement therapy.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Continuous Renal Replacement Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Incidence of Acute Kidney Injury Across the Globe
5.2. Rise in Prevalence of Diabetes and Hypertension
5.3. Reimbursement Scenario by Region/globally
5.4. Regulatory Scenario by Region/globally
5.5. Recent Technological Developments in Continuous Renal Replacement Therapy
5.6. Development of CRRT System for Pediatric Patients
5.7. Key Mergers & Acquisitions
6. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Mode
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Mode, 2017–2031
6.3.1. Slow Continuous Ultrafiltration (SCUF)
6.3.2. Continuous Venovenous Hemofiltration (CVVHF)
6.3.3. Continuous Venovenous Hemodialysis (CVVHD)
6.3.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
6.4. Market Attractiveness Analysis, by Mode
7. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017–2031
7.3.1. Dialysate & Replacement Fluids
7.3.2. Disposables
7.3.2.1. Bloodline Sets
7.3.2.2. Hemofilters
7.3.2.3. Other Disposables
7.3.3. Systems
7.4. Market Attractiveness Analysis, by Product
8. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Therapy
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Therapy, 2017–2031
8.3.1. Renal
8.3.2. Non-renal
8.3.3. Combination
8.4. Market Attractiveness Analysis, by Therapy
9. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Continuous Renal Replacement Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Mode, 2017–2031
11.2.1. Slow Continuous Ultrafiltration (SCUF)
11.2.2. Continuous Venovenous Hemofiltration (CVVHF)
11.2.3. Continuous Venovenous Hemodialysis (CVVHD)
11.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. Dialysate & Replacement Fluids
11.3.2. Disposables
11.3.2.1. Bloodline Sets
11.3.2.2. Hemofilters
11.3.2.3. Other Disposables
11.3.3. Systems
11.4. Market Value Forecast, by Therapy, 2017–2031
11.4.1. Renal
11.4.2. Non-renal
11.4.3. Combination
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Mode
11.7.2. By Product
11.7.3. By Therapy
11.7.4. By End-user
11.7.5. By Country
12. Europe Continuous Renal Replacement Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Mode, 2017–2031
12.2.1. Slow Continuous Ultrafiltration (SCUF)
12.2.2. Continuous Venovenous Hemofiltration (CVVHF)
12.2.3. Continuous Venovenous Hemodialysis (CVVHD)
12.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. Dialysate & Replacement Fluids
12.3.2. Disposables
12.3.2.1. Bloodline Sets
12.3.2.2. Hemofilters
12.3.2.3. Other Disposables
12.3.3. Systems
12.4. Market Value Forecast, by Therapy, 2017–2031
12.4.1. Renal
12.4.2. Non-renal
12.4.3. Combination
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Mode
12.7.2. By Product
12.7.3. By Therapy
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Continuous Renal Replacement Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Mode, 2017–2031
13.2.1. Slow Continuous Ultrafiltration (SCUF)
13.2.2. Continuous Venovenous Hemofiltration (CVVHF)
13.2.3. Continuous Venovenous Hemodialysis (CVVHD)
13.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. Dialysate & Replacement Fluids
13.3.2. Disposables
13.3.2.1. Bloodline Sets
13.3.2.2. Hemofilters
13.3.2.3. Other Disposables
13.3.3. Systems
13.4. Market Value Forecast, by Therapy, 2017–2031
13.4.1. Renal
13.4.2. Non-renal
13.4.3. Combination
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Mode
13.7.2. By Product
13.7.3. By Therapy
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Continuous Renal Replacement Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Mode, 2017–2031
14.2.1. Slow Continuous Ultrafiltration (SCUF)
14.2.2. Continuous Venovenous Hemofiltration (CVVHF)
14.2.3. Continuous Venovenous Hemodialysis (CVVHD)
14.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. Dialysate & Replacement Fluids
14.3.2. Disposables
14.3.2.1. Bloodline Sets
14.3.2.2. Hemofilters
14.3.2.3. Other Disposables
14.3.3. Systems
14.4. Market Value Forecast, by Therapy, 2017–2031
14.4.1. Renal
14.4.2. Non-renal
14.4.3. Combination
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Mode
14.7.2. By Product
14.7.3. By Therapy
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Mode, 2017–2031
15.2.1. Slow Continuous Ultrafiltration (SCUF)
15.2.2. Continuous Venovenous Hemofiltration (CVVHF)
15.2.3. Continuous Venovenous Hemodialysis (CVVHD)
15.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
15.3. Market Value Forecast, by Product, 2017–2031
15.3.1. Dialysate & Replacement Fluids
15.3.2. Disposables
15.3.2.1. Bloodline Sets
15.3.2.2. Hemofilters
15.3.2.3. Other Disposables
15.3.3. Systems
15.4. Market Value Forecast, by Therapy, 2017–2031
15.4.1. Renal
15.4.2. Non-renal
15.4.3. Combination
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Mode
15.7.2. By Product
15.7.3. By Therapy
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Position By Company (2021)
16.3. Company Profiles
16.3.1. Baxter International, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Nipro Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Asahi Kasei Corporation
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. B. Braun Melsungen AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Medica SPA
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. INFOMED SA
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Medtronic
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Toray Medical Company Limited (Toray Industries, Inc.)
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview